nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.175	0.5	CiPCiCtD
Pazopanib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.175	0.5	CiPCiCtD
Pazopanib—SH2B3—hematologic cancer	0.037	0.162	CbGaD
Pazopanib—LCK—hematologic cancer	0.0353	0.155	CbGaD
Pazopanib—FGF1—hematologic cancer	0.0315	0.138	CbGaD
Pazopanib—FGFR3—hematologic cancer	0.0296	0.13	CbGaD
Pazopanib—CSF1R—hematologic cancer	0.0213	0.0932	CbGaD
Pazopanib—PDGFRB—hematologic cancer	0.0185	0.0814	CbGaD
Pazopanib—PDGFRA—hematologic cancer	0.0181	0.0793	CbGaD
Pazopanib—KIT—hematologic cancer	0.0133	0.0582	CbGaD
Pazopanib—PIP4K2C—Imatinib—hematologic cancer	0.0131	0.0515	CbGbCtD
Pazopanib—UGT1A1—hematologic cancer	0.0131	0.0573	CbGaD
Pazopanib—STK16—Ruxolitinib—hematologic cancer	0.0123	0.0485	CbGbCtD
Pazopanib—STK36—Dasatinib—hematologic cancer	0.0105	0.0414	CbGbCtD
Pazopanib—LIMK2—Dasatinib—hematologic cancer	0.0105	0.0414	CbGbCtD
Pazopanib—FGFR2—Thalidomide—hematologic cancer	0.0104	0.0407	CbGbCtD
Pazopanib—BMPR1B—Dasatinib—hematologic cancer	0.00836	0.0329	CbGbCtD
Pazopanib—TAOK3—Ruxolitinib—hematologic cancer	0.0082	0.0323	CbGbCtD
Pazopanib—PLK4—Ruxolitinib—hematologic cancer	0.0082	0.0323	CbGbCtD
Pazopanib—ABCG2—hematologic cancer	0.00734	0.0322	CbGaD
Pazopanib—MAP3K2—Ruxolitinib—hematologic cancer	0.00709	0.0279	CbGbCtD
Pazopanib—EPHB6—Nilotinib—hematologic cancer	0.00605	0.0238	CbGbCtD
Pazopanib—LYN—Nilotinib—hematologic cancer	0.00605	0.0238	CbGbCtD
Pazopanib—MAP3K2—Dasatinib—hematologic cancer	0.00605	0.0238	CbGbCtD
Pazopanib—KIT—Imatinib—hematologic cancer	0.00598	0.0235	CbGbCtD
Pazopanib—PDGFRA—Imatinib—hematologic cancer	0.00598	0.0235	CbGbCtD
Pazopanib—CSF1R—Imatinib—hematologic cancer	0.00598	0.0235	CbGbCtD
Pazopanib—LCK—Imatinib—hematologic cancer	0.00544	0.0214	CbGbCtD
Pazopanib—PDGFRB—Imatinib—hematologic cancer	0.00544	0.0214	CbGbCtD
Pazopanib—KIT—Nilotinib—hematologic cancer	0.00544	0.0214	CbGbCtD
Pazopanib—PDGFRA—Nilotinib—hematologic cancer	0.00544	0.0214	CbGbCtD
Pazopanib—CSF1R—Nilotinib—hematologic cancer	0.00544	0.0214	CbGbCtD
Pazopanib—EPHB6—Dasatinib—hematologic cancer	0.00535	0.021	CbGbCtD
Pazopanib—LYN—Dasatinib—hematologic cancer	0.00535	0.021	CbGbCtD
Pazopanib—MAP2K5—Nilotinib—hematologic cancer	0.00495	0.0195	CbGbCtD
Pazopanib—PDGFRB—Nilotinib—hematologic cancer	0.00495	0.0195	CbGbCtD
Pazopanib—LCK—Nilotinib—hematologic cancer	0.00495	0.0195	CbGbCtD
Pazopanib—KIT—Dasatinib—hematologic cancer	0.0048	0.0189	CbGbCtD
Pazopanib—PDGFRA—Dasatinib—hematologic cancer	0.0048	0.0189	CbGbCtD
Pazopanib—CSF1R—Dasatinib—hematologic cancer	0.0048	0.0189	CbGbCtD
Pazopanib—MAP3K19—Ruxolitinib—hematologic cancer	0.00471	0.0185	CbGbCtD
Pazopanib—MAP2K5—Dasatinib—hematologic cancer	0.00437	0.0172	CbGbCtD
Pazopanib—LCK—Dasatinib—hematologic cancer	0.00437	0.0172	CbGbCtD
Pazopanib—PDGFRB—Dasatinib—hematologic cancer	0.00437	0.0172	CbGbCtD
Pazopanib—MAP3K19—Dasatinib—hematologic cancer	0.00402	0.0158	CbGbCtD
Pazopanib—ABCB1—hematologic cancer	0.00306	0.0134	CbGaD
Pazopanib—BMPR1B—ovarian follicle—hematologic cancer	0.00265	0.0843	CbGeAlD
Pazopanib—ABCG2—Clofarabine—hematologic cancer	0.0022	0.00865	CbGbCtD
Pazopanib—UGT1A1—Nilotinib—hematologic cancer	0.00163	0.00642	CbGbCtD
Pazopanib—CYP1A2—Anagrelide—hematologic cancer	0.00131	0.00515	CbGbCtD
Pazopanib—ABCG2—Daunorubicin—hematologic cancer	0.00129	0.00507	CbGbCtD
Pazopanib—UGT1A1—Irinotecan—hematologic cancer	0.00112	0.00441	CbGbCtD
Pazopanib—ABCG2—Teniposide—hematologic cancer	0.00112	0.00441	CbGbCtD
Pazopanib—ABCG2—Cladribine—hematologic cancer	0.00107	0.00422	CbGbCtD
Pazopanib—ABCG2—Imatinib—hematologic cancer	0.000988	0.00388	CbGbCtD
Pazopanib—UGT1A1—Etoposide—hematologic cancer	0.000898	0.00353	CbGbCtD
Pazopanib—ABCG2—Nilotinib—hematologic cancer	0.000898	0.00353	CbGbCtD
Pazopanib—ABCG2—Dasatinib—hematologic cancer	0.000793	0.00312	CbGbCtD
Pazopanib—ABCB1—Lenalidomide—hematologic cancer	0.000793	0.00312	CbGbCtD
Pazopanib—ABCG2—Mitoxantrone—hematologic cancer	0.000784	0.00308	CbGbCtD
Pazopanib—SLCO1B1—Irinotecan—hematologic cancer	0.000777	0.00305	CbGbCtD
Pazopanib—CYP2C8—Bortezomib—hematologic cancer	0.000718	0.00282	CbGbCtD
Pazopanib—CYP2D6—Lomustine—hematologic cancer	0.000695	0.00273	CbGbCtD
Pazopanib—CYP1A2—Carmustine—hematologic cancer	0.000687	0.0027	CbGbCtD
Pazopanib—CYP2D6—Idarubicin—hematologic cancer	0.000619	0.00243	CbGbCtD
Pazopanib—ABCG2—Irinotecan—hematologic cancer	0.000617	0.00243	CbGbCtD
Pazopanib—CYP1A2—Methoxsalen—hematologic cancer	0.000584	0.0023	CbGbCtD
Pazopanib—CYP1A2—Bortezomib—hematologic cancer	0.000556	0.00219	CbGbCtD
Pazopanib—CYP2C8—Ifosfamide—hematologic cancer	0.000551	0.00217	CbGbCtD
Pazopanib—ABCG2—Vincristine—hematologic cancer	0.000539	0.00212	CbGbCtD
Pazopanib—CYP1A2—Daunorubicin—hematologic cancer	0.000532	0.00209	CbGbCtD
Pazopanib—CYP2D6—Hydroxyurea—hematologic cancer	0.000526	0.00207	CbGbCtD
Pazopanib—CYP1A2—Alitretinoin—hematologic cancer	0.000521	0.00205	CbGbCtD
Pazopanib—ABCG2—Cisplatin—hematologic cancer	0.000503	0.00198	CbGbCtD
Pazopanib—ABCG2—Etoposide—hematologic cancer	0.000494	0.00194	CbGbCtD
Pazopanib—CYP1A2—Thalidomide—hematologic cancer	0.000484	0.0019	CbGbCtD
Pazopanib—CYP2C8—Nilotinib—hematologic cancer	0.000478	0.00188	CbGbCtD
Pazopanib—CYP3A4—Bexarotene—hematologic cancer	0.000475	0.00187	CbGbCtD
Pazopanib—ABCB1—Daunorubicin—hematologic cancer	0.000465	0.00183	CbGbCtD
Pazopanib—CYP2D6—Bortezomib—hematologic cancer	0.000458	0.0018	CbGbCtD
Pazopanib—ABCB1—Alitretinoin—hematologic cancer	0.000455	0.00179	CbGbCtD
Pazopanib—ITK—hematopoietic system—hematologic cancer	0.00045	0.0143	CbGeAlD
Pazopanib—CYP3A4—Lomustine—hematologic cancer	0.000442	0.00174	CbGbCtD
Pazopanib—CYP3A4—Busulfan—hematologic cancer	0.000442	0.00174	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—hematologic cancer	0.000416	0.00164	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—hematologic cancer	0.000411	0.00162	CbGbCtD
Pazopanib—TAOK1—hematopoietic system—hematologic cancer	0.000409	0.013	CbGeAlD
Pazopanib—CYP1A2—Imatinib—hematologic cancer	0.000407	0.0016	CbGbCtD
Pazopanib—ABCG2—Dexamethasone—hematologic cancer	0.000406	0.0016	CbGbCtD
Pazopanib—CYP3A4—Thiotepa—hematologic cancer	0.000394	0.00155	CbGbCtD
Pazopanib—SH2B3—hematopoietic system—hematologic cancer	0.000385	0.0123	CbGeAlD
Pazopanib—Rilpivirine—ABCG2—hematologic cancer	0.000378	0.706	CrCbGaD
Pazopanib—ABCB1—Imatinib—hematologic cancer	0.000356	0.0014	CbGbCtD
Pazopanib—PLK4—hematopoietic system—hematologic cancer	0.000347	0.0111	CbGeAlD
Pazopanib—ABCG2—Doxorubicin—hematologic cancer	0.000337	0.00133	CbGbCtD
Pazopanib—CYP2D6—Imatinib—hematologic cancer	0.000336	0.00132	CbGbCtD
Pazopanib—STK16—hematopoietic system—hematologic cancer	0.000328	0.0104	CbGeAlD
Pazopanib—CYP1A2—Dasatinib—hematologic cancer	0.000327	0.00129	CbGbCtD
Pazopanib—ABCG2—Methotrexate—hematologic cancer	0.000326	0.00128	CbGbCtD
Pazopanib—LYN—hematopoietic system—hematologic cancer	0.000324	0.0103	CbGeAlD
Pazopanib—ABCB1—Nilotinib—hematologic cancer	0.000324	0.00127	CbGbCtD
Pazopanib—FGFR3—hematopoietic system—hematologic cancer	0.000323	0.0103	CbGeAlD
Pazopanib—ABCB1—Vinorelbine—hematologic cancer	0.000321	0.00126	CbGbCtD
Pazopanib—MAP3K9—lung—hematologic cancer	0.000317	0.0101	CbGeAlD
Pazopanib—TAOK1—gonad—hematologic cancer	0.000311	0.00992	CbGeAlD
Pazopanib—CYP3A4—Methoxsalen—hematologic cancer	0.000306	0.0012	CbGbCtD
Pazopanib—CYP2D6—Nilotinib—hematologic cancer	0.000305	0.0012	CbGbCtD
Pazopanib—CYP2D6—Vinorelbine—hematologic cancer	0.000302	0.00119	CbGbCtD
Pazopanib—MAP3K9—testis—hematologic cancer	0.000299	0.00952	CbGeAlD
Pazopanib—ITK—blood—hematologic cancer	0.000298	0.00949	CbGeAlD
Pazopanib—CYP3A4—Bortezomib—hematologic cancer	0.000291	0.00115	CbGbCtD
Pazopanib—AURKC—gonad—hematologic cancer	0.000289	0.00919	CbGeAlD
Pazopanib—ITK—bone marrow—hematologic cancer	0.000288	0.00919	CbGeAlD
Pazopanib—ABCB1—Dasatinib—hematologic cancer	0.000286	0.00112	CbGbCtD
Pazopanib—ABCB1—Mitoxantrone—hematologic cancer	0.000283	0.00111	CbGbCtD
Pazopanib—LIMK2—hematopoietic system—hematologic cancer	0.00028	0.00893	CbGeAlD
Pazopanib—CYP3A4—Daunorubicin—hematologic cancer	0.000279	0.0011	CbGbCtD
Pazopanib—TAOK1—blood—hematologic cancer	0.000271	0.00864	CbGeAlD
Pazopanib—PLK4—gonad—hematologic cancer	0.000264	0.00841	CbGeAlD
Pazopanib—CYP2C8—Etoposide—hematologic cancer	0.000263	0.00104	CbGbCtD
Pazopanib—TAOK1—bone marrow—hematologic cancer	0.000262	0.00836	CbGeAlD
Pazopanib—ITK—lung—hematologic cancer	0.000261	0.00832	CbGeAlD
Pazopanib—SH2B3—blood—hematologic cancer	0.000255	0.00814	CbGeAlD
Pazopanib—ABCB1—Betamethasone—hematologic cancer	0.000252	0.00099	CbGbCtD
Pazopanib—FLT4—hematopoietic system—hematologic cancer	0.000252	0.00802	CbGeAlD
Pazopanib—ABCB1—Gemcitabine—hematologic cancer	0.00025	0.000981	CbGbCtD
Pazopanib—ABCB1—Prednisolone—hematologic cancer	0.000248	0.000977	CbGbCtD
Pazopanib—SH2B3—bone marrow—hematologic cancer	0.000247	0.00787	CbGeAlD
Pazopanib—ITK—testis—hematologic cancer	0.000246	0.00785	CbGeAlD
Pazopanib—CYP3A4—Cytarabine—hematologic cancer	0.000246	0.000966	CbGbCtD
Pazopanib—FGFR3—gonad—hematologic cancer	0.000245	0.00782	CbGeAlD
Pazopanib—CYP3A4—Teniposide—hematologic cancer	0.000242	0.000952	CbGbCtD
Pazopanib—TAOK1—lung—hematologic cancer	0.000238	0.00758	CbGeAlD
Pazopanib—MAP3K2—hematopoietic system—hematologic cancer	0.000237	0.00756	CbGeAlD
Pazopanib—ABCB1—Prednisone—hematologic cancer	0.000235	0.000923	CbGbCtD
Pazopanib—PLK4—blood—hematologic cancer	0.00023	0.00733	CbGeAlD
Pazopanib—TAOK1—testis—hematologic cancer	0.000224	0.00715	CbGeAlD
Pazopanib—SH2B3—lung—hematologic cancer	0.000224	0.00713	CbGeAlD
Pazopanib—FGF1—hematopoietic system—hematologic cancer	0.000224	0.00713	CbGeAlD
Pazopanib—CYP3A4—Ifosfamide—hematologic cancer	0.000223	0.000878	CbGbCtD
Pazopanib—PLK4—bone marrow—hematologic cancer	0.000222	0.00709	CbGeAlD
Pazopanib—ABCB1—Irinotecan—hematologic cancer	0.000222	0.000875	CbGbCtD
Pazopanib—STK36—gonad—hematologic cancer	0.00022	0.00702	CbGeAlD
Pazopanib—STK16—blood—hematologic cancer	0.000217	0.00692	CbGeAlD
Pazopanib—PI4KB—gonad—hematologic cancer	0.000217	0.00691	CbGeAlD
Pazopanib—MAP3K9—lymph node—hematologic cancer	0.000217	0.0069	CbGeAlD
Pazopanib—CYP2C8—Dexamethasone—hematologic cancer	0.000216	0.000851	CbGbCtD
Pazopanib—LYN—blood—hematologic cancer	0.000215	0.00685	CbGeAlD
Pazopanib—RIOK2—blood—hematologic cancer	0.000214	0.00681	CbGeAlD
Pazopanib—CYP3A4—Imatinib—hematologic cancer	0.000213	0.000839	CbGbCtD
Pazopanib—LIMK2—gonad—hematologic cancer	0.000213	0.00679	CbGeAlD
Pazopanib—SH2B3—testis—hematologic cancer	0.000211	0.00673	CbGeAlD
Pazopanib—FGFR2—hematopoietic system—hematologic cancer	0.000211	0.00673	CbGeAlD
Pazopanib—AURKC—testis—hematologic cancer	0.000208	0.00663	CbGeAlD
Pazopanib—RIOK2—bone marrow—hematologic cancer	0.000207	0.00659	CbGeAlD
Pazopanib—CYP1A2—Etoposide—hematologic cancer	0.000204	0.000801	CbGbCtD
Pazopanib—PLK4—lung—hematologic cancer	0.000202	0.00642	CbGeAlD
Pazopanib—CYP3A4—Ruxolitinib—hematologic cancer	0.000201	0.00079	CbGbCtD
Pazopanib—ABCB1—Vinblastine—hematologic cancer	0.000198	0.000778	CbGbCtD
Pazopanib—FLT1—hematopoietic system—hematologic cancer	0.000196	0.00624	CbGeAlD
Pazopanib—ABCB1—Vincristine—hematologic cancer	0.000194	0.000765	CbGbCtD
Pazopanib—CYP3A4—Nilotinib—hematologic cancer	0.000194	0.000762	CbGbCtD
Pazopanib—CYP3A4—Vinorelbine—hematologic cancer	0.000192	0.000756	CbGbCtD
Pazopanib—STK36—blood—hematologic cancer	0.000192	0.00612	CbGeAlD
Pazopanib—PIP4K2C—gonad—hematologic cancer	0.00019	0.00607	CbGeAlD
Pazopanib—STK16—lung—hematologic cancer	0.00019	0.00607	CbGeAlD
Pazopanib—PLK4—testis—hematologic cancer	0.00019	0.00606	CbGeAlD
Pazopanib—PI4KB—blood—hematologic cancer	0.000189	0.00602	CbGeAlD
Pazopanib—RIOK2—lung—hematologic cancer	0.000187	0.00597	CbGeAlD
Pazopanib—FGFR3—lung—hematologic cancer	0.000187	0.00597	CbGeAlD
Pazopanib—CYP2D6—Vinblastine—hematologic cancer	0.000186	0.000733	CbGbCtD
Pazopanib—LIMK2—blood—hematologic cancer	0.000186	0.00591	CbGeAlD
Pazopanib—MAP3K19—lung—hematologic cancer	0.000186	0.00591	CbGeAlD
Pazopanib—BMPR1B—lung—hematologic cancer	0.000186	0.00591	CbGeAlD
Pazopanib—STK10—hematopoietic system—hematologic cancer	0.000185	0.0059	CbGeAlD
Pazopanib—TAOK3—hematopoietic system—hematologic cancer	0.000185	0.00588	CbGeAlD
Pazopanib—PDGFRA—hematopoietic system—hematologic cancer	0.000183	0.00585	CbGeAlD
Pazopanib—PI4KB—bone marrow—hematologic cancer	0.000183	0.00583	CbGeAlD
Pazopanib—ABCB1—Cisplatin—hematologic cancer	0.000181	0.000713	CbGbCtD
Pazopanib—MAP3K2—gonad—hematologic cancer	0.00018	0.00575	CbGeAlD
Pazopanib—STK16—testis—hematologic cancer	0.00018	0.00572	CbGeAlD
Pazopanib—ITK—lymph node—hematologic cancer	0.000179	0.00569	CbGeAlD
Pazopanib—ABCB1—Etoposide—hematologic cancer	0.000178	0.000701	CbGbCtD
Pazopanib—RIOK2—testis—hematologic cancer	0.000177	0.00563	CbGeAlD
Pazopanib—FGFR3—testis—hematologic cancer	0.000177	0.00563	CbGeAlD
Pazopanib—CYP3A4—Triamcinolone—hematologic cancer	0.000176	0.000692	CbGbCtD
Pazopanib—BMPR1B—testis—hematologic cancer	0.000175	0.00558	CbGeAlD
Pazopanib—MAP3K19—testis—hematologic cancer	0.000175	0.00558	CbGeAlD
Pazopanib—UGT1A1—hematopoietic system—hematologic cancer	0.000175	0.00558	CbGeAlD
Pazopanib—CYP3A4—Dasatinib—hematologic cancer	0.000171	0.000674	CbGbCtD
Pazopanib—CYP3A4—Mitoxantrone—hematologic cancer	0.000169	0.000666	CbGbCtD
Pazopanib—STK36—lung—hematologic cancer	0.000168	0.00536	CbGeAlD
Pazopanib—FLT4—blood—hematologic cancer	0.000167	0.00532	CbGeAlD
Pazopanib—PIP4K2C—blood—hematologic cancer	0.000166	0.00529	CbGeAlD
Pazopanib—PI4KB—lung—hematologic cancer	0.000166	0.00528	CbGeAlD
Pazopanib—KDR—hematopoietic system—hematologic cancer	0.000165	0.00527	CbGeAlD
Pazopanib—LIMK2—lung—hematologic cancer	0.000163	0.00519	CbGeAlD
Pazopanib—TAOK1—lymph node—hematologic cancer	0.000163	0.00518	CbGeAlD
Pazopanib—CSF1R—hematopoietic system—hematologic cancer	0.000162	0.00515	CbGeAlD
Pazopanib—FLT4—bone marrow—hematologic cancer	0.000161	0.00514	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—hematologic cancer	0.000161	0.00512	CbGeAlD
Pazopanib—STK36—testis—hematologic cancer	0.000159	0.00506	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—hematologic cancer	0.000157	0.294	CrCbGaD
Pazopanib—MAP3K2—blood—hematologic cancer	0.000157	0.00501	CbGeAlD
Pazopanib—PI4KB—testis—hematologic cancer	0.000156	0.00498	CbGeAlD
Pazopanib—LIMK2—testis—hematologic cancer	0.000154	0.00489	CbGeAlD
Pazopanib—SH2B3—lymph node—hematologic cancer	0.000153	0.00488	CbGeAlD
Pazopanib—MAP3K2—bone marrow—hematologic cancer	0.000152	0.00485	CbGeAlD
Pazopanib—CYP3A4—Betamethasone—hematologic cancer	0.000151	0.000593	CbGbCtD
Pazopanib—AURKC—lymph node—hematologic cancer	0.000151	0.0048	CbGeAlD
Pazopanib—CYP3A4—Prednisolone—hematologic cancer	0.000149	0.000585	CbGbCtD
Pazopanib—FLT1—gonad—hematologic cancer	0.000149	0.00474	CbGeAlD
Pazopanib—FGF1—blood—hematologic cancer	0.000148	0.00472	CbGeAlD
Pazopanib—LCK—blood—hematologic cancer	0.000147	0.00469	CbGeAlD
Pazopanib—KIT—hematopoietic system—hematologic cancer	0.000147	0.00467	CbGeAlD
Pazopanib—ABCB1—Dexamethasone—hematologic cancer	0.000146	0.000576	CbGbCtD
Pazopanib—FLT4—lung—hematologic cancer	0.000146	0.00466	CbGeAlD
Pazopanib—SLCO1B1—hematopoietic system—hematologic cancer	0.000146	0.00464	CbGeAlD
Pazopanib—PIP4K2C—lung—hematologic cancer	0.000145	0.00463	CbGeAlD
Pazopanib—FGFR1—lung—hematologic cancer	0.000144	0.0046	CbGeAlD
Pazopanib—PDGFRB—hematopoietic system—hematologic cancer	0.000143	0.00456	CbGeAlD
Pazopanib—LCK—bone marrow—hematologic cancer	0.000143	0.00454	CbGeAlD
Pazopanib—STK10—gonad—hematologic cancer	0.000141	0.00449	CbGeAlD
Pazopanib—CYP3A4—Prednisone—hematologic cancer	0.000141	0.000553	CbGbCtD
Pazopanib—FGFR2—blood—hematologic cancer	0.00014	0.00446	CbGeAlD
Pazopanib—PDGFRA—gonad—hematologic cancer	0.000139	0.00444	CbGeAlD
Pazopanib—CYP2D6—Dexamethasone—hematologic cancer	0.000138	0.000543	CbGbCtD
Pazopanib—FLT4—testis—hematologic cancer	0.000138	0.0044	CbGeAlD
Pazopanib—MAP3K2—lung—hematologic cancer	0.000138	0.00439	CbGeAlD
Pazopanib—PLK4—lymph node—hematologic cancer	0.000138	0.00439	CbGeAlD
Pazopanib—PIP4K2C—testis—hematologic cancer	0.000137	0.00437	CbGeAlD
Pazopanib—FGFR1—testis—hematologic cancer	0.000136	0.00434	CbGeAlD
Pazopanib—CYP3A4—Irinotecan—hematologic cancer	0.000133	0.000524	CbGbCtD
Pazopanib—STK16—lymph node—hematologic cancer	0.00013	0.00415	CbGeAlD
Pazopanib—MAP3K2—testis—hematologic cancer	0.00013	0.00415	CbGeAlD
Pazopanib—FGF1—lung—hematologic cancer	0.00013	0.00414	CbGeAlD
Pazopanib—FLT1—blood—hematologic cancer	0.00013	0.00413	CbGeAlD
Pazopanib—LCK—lung—hematologic cancer	0.000129	0.00411	CbGeAlD
Pazopanib—EPHB6—blood—hematologic cancer	0.000128	0.00409	CbGeAlD
Pazopanib—RIOK2—lymph node—hematologic cancer	0.000128	0.00408	CbGeAlD
Pazopanib—BMPR1B—lymph node—hematologic cancer	0.000127	0.00404	CbGeAlD
Pazopanib—CSF1R—gonad—hematologic cancer	0.000123	0.00391	CbGeAlD
Pazopanib—STK10—blood—hematologic cancer	0.000123	0.00391	CbGeAlD
Pazopanib—FGFR2—lung—hematologic cancer	0.000123	0.00391	CbGeAlD
Pazopanib—FGF1—testis—hematologic cancer	0.000123	0.00391	CbGeAlD
Pazopanib—TAOK3—blood—hematologic cancer	0.000122	0.0039	CbGeAlD
Pazopanib—LCK—testis—hematologic cancer	0.000122	0.00388	CbGeAlD
Pazopanib—PDGFRA—blood—hematologic cancer	0.000122	0.00387	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—hematologic cancer	0.000122	0.000478	CbGbCtD
Pazopanib—PLK4—Topotecan—Irinotecan—hematologic cancer	0.000119	0.121	CbGdCrCtD
Pazopanib—STK10—bone marrow—hematologic cancer	0.000119	0.00379	CbGeAlD
Pazopanib—PLK4—Etoposide—Teniposide—hematologic cancer	0.000119	0.12	CbGdCrCtD
Pazopanib—CYP3A4—Vinblastine—hematologic cancer	0.000118	0.000466	CbGbCtD
Pazopanib—TAOK3—bone marrow—hematologic cancer	0.000118	0.00377	CbGeAlD
Pazopanib—ABCB1—Methotrexate—hematologic cancer	0.000118	0.000463	CbGbCtD
Pazopanib—CYP3A4—Vincristine—hematologic cancer	0.000116	0.000458	CbGbCtD
Pazopanib—UGT1A1—blood—hematologic cancer	0.000116	0.00369	CbGeAlD
Pazopanib—FGFR2—testis—hematologic cancer	0.000116	0.00369	CbGeAlD
Pazopanib—STK36—lymph node—hematologic cancer	0.000115	0.00367	CbGeAlD
Pazopanib—CYP2D6—Doxorubicin—hematologic cancer	0.000115	0.00045	CbGbCtD
Pazopanib—FLT1—lung—hematologic cancer	0.000114	0.00362	CbGeAlD
Pazopanib—PI4KB—lymph node—hematologic cancer	0.000113	0.00361	CbGeAlD
Pazopanib—EPHB6—lung—hematologic cancer	0.000112	0.00358	CbGeAlD
Pazopanib—KIT—gonad—hematologic cancer	0.000112	0.00355	CbGeAlD
Pazopanib—LIMK2—lymph node—hematologic cancer	0.000111	0.00355	CbGeAlD
Pazopanib—MAP2K5—blood—hematologic cancer	0.00011	0.00349	CbGeAlD
Pazopanib—KDR—blood—hematologic cancer	0.00011	0.00349	CbGeAlD
Pazopanib—PDGFRB—gonad—hematologic cancer	0.000109	0.00347	CbGeAlD
Pazopanib—STK10—lung—hematologic cancer	0.000108	0.00343	CbGeAlD
Pazopanib—FLT1—testis—hematologic cancer	0.000107	0.00342	CbGeAlD
Pazopanib—TAOK3—lung—hematologic cancer	0.000107	0.00342	CbGeAlD
Pazopanib—CSF1R—blood—hematologic cancer	0.000107	0.00341	CbGeAlD
Pazopanib—CYP3A4—Etoposide—hematologic cancer	0.000107	0.00042	CbGbCtD
Pazopanib—PDGFRA—lung—hematologic cancer	0.000107	0.00339	CbGeAlD
Pazopanib—KDR—bone marrow—hematologic cancer	0.000106	0.00338	CbGeAlD
Pazopanib—EPHB6—testis—hematologic cancer	0.000106	0.00338	CbGeAlD
Pazopanib—CSF1R—bone marrow—hematologic cancer	0.000104	0.0033	CbGeAlD
Pazopanib—STK10—testis—hematologic cancer	0.000102	0.00324	CbGeAlD
Pazopanib—TAOK3—testis—hematologic cancer	0.000101	0.00322	CbGeAlD
Pazopanib—PDGFRA—testis—hematologic cancer	0.000101	0.0032	CbGeAlD
Pazopanib—FLT4—lymph node—hematologic cancer	0.0001	0.00319	CbGeAlD
Pazopanib—PIP4K2C—lymph node—hematologic cancer	9.95e-05	0.00317	CbGeAlD
Pazopanib—FGFR1—lymph node—hematologic cancer	9.87e-05	0.00314	CbGeAlD
Pazopanib—KIT—blood—hematologic cancer	9.72e-05	0.0031	CbGeAlD
Pazopanib—SLCO1B1—blood—hematologic cancer	9.65e-05	0.00307	CbGeAlD
Pazopanib—KDR—lung—hematologic cancer	9.61e-05	0.00306	CbGeAlD
Pazopanib—MAP2K5—lung—hematologic cancer	9.61e-05	0.00306	CbGeAlD
Pazopanib—PDGFRB—blood—hematologic cancer	9.49e-05	0.00302	CbGeAlD
Pazopanib—MAP3K2—lymph node—hematologic cancer	9.43e-05	0.003	CbGeAlD
Pazopanib—KIT—bone marrow—hematologic cancer	9.4e-05	0.003	CbGeAlD
Pazopanib—CSF1R—lung—hematologic cancer	9.38e-05	0.00299	CbGeAlD
Pazopanib—PDGFRB—bone marrow—hematologic cancer	9.18e-05	0.00293	CbGeAlD
Pazopanib—KDR—testis—hematologic cancer	9.07e-05	0.00289	CbGeAlD
Pazopanib—MAP2K5—testis—hematologic cancer	9.07e-05	0.00289	CbGeAlD
Pazopanib—FGF1—lymph node—hematologic cancer	8.88e-05	0.00283	CbGeAlD
Pazopanib—CSF1R—testis—hematologic cancer	8.85e-05	0.00282	CbGeAlD
Pazopanib—LCK—lymph node—hematologic cancer	8.83e-05	0.00281	CbGeAlD
Pazopanib—CYP3A4—Dexamethasone—hematologic cancer	8.78e-05	0.000345	CbGbCtD
Pazopanib—KIT—lung—hematologic cancer	8.52e-05	0.00271	CbGeAlD
Pazopanib—PDGFRB—lung—hematologic cancer	8.32e-05	0.00265	CbGeAlD
Pazopanib—CYP2C8—hematopoietic system—hematologic cancer	8.28e-05	0.00264	CbGeAlD
Pazopanib—PLK4—Idarubicin—Daunorubicin—hematologic cancer	8.06e-05	0.0817	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Daunorubicin—hematologic cancer	8.06e-05	0.0817	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Daunorubicin—hematologic cancer	8.06e-05	0.0817	CbGdCrCtD
Pazopanib—KIT—testis—hematologic cancer	8.04e-05	0.00256	CbGeAlD
Pazopanib—PDGFRB—testis—hematologic cancer	7.85e-05	0.0025	CbGeAlD
Pazopanib—FLT1—lymph node—hematologic cancer	7.78e-05	0.00248	CbGeAlD
Pazopanib—CYP1A2—hematopoietic system—hematologic cancer	7.75e-05	0.00247	CbGeAlD
Pazopanib—EPHB6—lymph node—hematologic cancer	7.69e-05	0.00245	CbGeAlD
Pazopanib—STK10—lymph node—hematologic cancer	7.36e-05	0.00235	CbGeAlD
Pazopanib—TAOK3—lymph node—hematologic cancer	7.33e-05	0.00234	CbGeAlD
Pazopanib—PDGFRA—lymph node—hematologic cancer	7.29e-05	0.00232	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—hematologic cancer	7.28e-05	0.000286	CbGbCtD
Pazopanib—PLK4—Menadione—Thalidomide—hematologic cancer	6.85e-05	0.0695	CbGdCrCtD
Pazopanib—KDR—lymph node—hematologic cancer	6.57e-05	0.00209	CbGeAlD
Pazopanib—MAP2K5—lymph node—hematologic cancer	6.57e-05	0.00209	CbGeAlD
Pazopanib—CSF1R—lymph node—hematologic cancer	6.42e-05	0.00204	CbGeAlD
Pazopanib—PLK4—Epirubicin—Idarubicin—hematologic cancer	6.11e-05	0.0619	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Idarubicin—hematologic cancer	6.11e-05	0.0619	CbGdCrCtD
Pazopanib—KIT—lymph node—hematologic cancer	5.83e-05	0.00186	CbGeAlD
Pazopanib—PDGFRB—lymph node—hematologic cancer	5.69e-05	0.00181	CbGeAlD
Pazopanib—CYP3A4—hematopoietic system—hematologic cancer	5.61e-05	0.00179	CbGeAlD
Pazopanib—CYP2D6—hematopoietic system—hematologic cancer	5.52e-05	0.00176	CbGeAlD
Pazopanib—CYP2C8—blood—hematologic cancer	5.49e-05	0.00175	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—hematologic cancer	5.38e-05	0.0545	CbGdCrCtD
Pazopanib—ABCG2—blood—hematologic cancer	5.33e-05	0.0017	CbGeAlD
Pazopanib—ABCG2—bone marrow—hematologic cancer	5.16e-05	0.00164	CbGeAlD
Pazopanib—CYP1A2—blood—hematologic cancer	5.13e-05	0.00164	CbGeAlD
Pazopanib—ABCG2—lung—hematologic cancer	4.68e-05	0.00149	CbGeAlD
Pazopanib—CYP2C8—testis—hematologic cancer	4.54e-05	0.00145	CbGeAlD
Pazopanib—CYP1A2—lung—hematologic cancer	4.5e-05	0.00143	CbGeAlD
Pazopanib—ABCG2—testis—hematologic cancer	4.41e-05	0.00141	CbGeAlD
Pazopanib—ABCB1—hematopoietic system—hematologic cancer	3.97e-05	0.00126	CbGeAlD
Pazopanib—CYP3A4—blood—hematologic cancer	3.72e-05	0.00118	CbGeAlD
Pazopanib—CYP2D6—blood—hematologic cancer	3.66e-05	0.00117	CbGeAlD
Pazopanib—ABCG2—lymph node—hematologic cancer	3.2e-05	0.00102	CbGeAlD
Pazopanib—CYP2D6—testis—hematologic cancer	3.02e-05	0.000964	CbGeAlD
Pazopanib—ABCB1—gonad—hematologic cancer	3.02e-05	0.000962	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—hematologic cancer	2.8e-05	0.0284	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—hematologic cancer	2.8e-05	0.0284	CbGdCrCtD
Pazopanib—ABCB1—blood—hematologic cancer	2.63e-05	0.000838	CbGeAlD
Pazopanib—PLK4—Idarubicin—Doxorubicin—hematologic cancer	2.59e-05	0.0263	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—hematologic cancer	2.59e-05	0.0263	CbGdCrCtD
Pazopanib—ABCB1—bone marrow—hematologic cancer	2.55e-05	0.000811	CbGeAlD
Pazopanib—ABCB1—lung—hematologic cancer	2.31e-05	0.000735	CbGeAlD
Pazopanib—ABCB1—testis—hematologic cancer	2.18e-05	0.000693	CbGeAlD
Pazopanib—SH2B3—Betamethasone—Dexamethasone—hematologic cancer	2.03e-05	0.0205	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Betamethasone—hematologic cancer	2.03e-05	0.0205	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Triamcinolone—hematologic cancer	1.98e-05	0.0201	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Triamcinolone—hematologic cancer	1.98e-05	0.0201	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisone—hematologic cancer	1.88e-05	0.019	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisone—hematologic cancer	1.88e-05	0.019	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisolone—hematologic cancer	1.83e-05	0.0186	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisolone—hematologic cancer	1.83e-05	0.0186	CbGdCrCtD
Pazopanib—ABCB1—lymph node—hematologic cancer	1.58e-05	0.000502	CbGeAlD
Pazopanib—Vomiting—Gemcitabine—hematologic cancer	4.78e-06	6.75e-05	CcSEcCtD
Pazopanib—Insomnia—Dexamethasone—hematologic cancer	4.78e-06	6.75e-05	CcSEcCtD
Pazopanib—Insomnia—Betamethasone—hematologic cancer	4.78e-06	6.75e-05	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—hematologic cancer	4.77e-06	6.74e-05	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.77e-06	6.73e-05	CcSEcCtD
Pazopanib—Paraesthesia—Dexamethasone—hematologic cancer	4.74e-06	6.7e-05	CcSEcCtD
Pazopanib—Paraesthesia—Betamethasone—hematologic cancer	4.74e-06	6.7e-05	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—hematologic cancer	4.74e-06	6.7e-05	CcSEcCtD
Pazopanib—Rash—Gemcitabine—hematologic cancer	4.74e-06	6.7e-05	CcSEcCtD
Pazopanib—Dermatitis—Gemcitabine—hematologic cancer	4.74e-06	6.69e-05	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—hematologic cancer	4.73e-06	6.69e-05	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—hematologic cancer	4.71e-06	6.66e-05	CcSEcCtD
Pazopanib—Erythema—Methotrexate—hematologic cancer	4.71e-06	6.66e-05	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—hematologic cancer	4.71e-06	6.65e-05	CcSEcCtD
Pazopanib—Headache—Gemcitabine—hematologic cancer	4.71e-06	6.65e-05	CcSEcCtD
Pazopanib—Nausea—Vincristine—hematologic cancer	4.71e-06	6.65e-05	CcSEcCtD
Pazopanib—Flushing—Epirubicin—hematologic cancer	4.7e-06	6.64e-05	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—hematologic cancer	4.7e-06	6.64e-05	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—hematologic cancer	4.69e-06	6.62e-05	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—hematologic cancer	4.66e-06	6.59e-05	CcSEcCtD
Pazopanib—Dyspepsia—Betamethasone—hematologic cancer	4.65e-06	6.57e-05	CcSEcCtD
Pazopanib—Dyspepsia—Dexamethasone—hematologic cancer	4.65e-06	6.57e-05	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—hematologic cancer	4.63e-06	6.54e-05	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—hematologic cancer	4.62e-06	6.52e-05	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—hematologic cancer	4.61e-06	6.52e-05	CcSEcCtD
Pazopanib—Asthenia—Etoposide—hematologic cancer	4.61e-06	6.51e-05	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—hematologic cancer	4.61e-06	6.51e-05	CcSEcCtD
Pazopanib—Oedema—Prednisone—hematologic cancer	4.6e-06	6.5e-05	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—hematologic cancer	4.6e-06	6.49e-05	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—hematologic cancer	4.59e-06	6.49e-05	CcSEcCtD
Pazopanib—Decreased appetite—Betamethasone—hematologic cancer	4.59e-06	6.49e-05	CcSEcCtD
Pazopanib—Decreased appetite—Dexamethasone—hematologic cancer	4.59e-06	6.49e-05	CcSEcCtD
Pazopanib—Nausea—Mitoxantrone—hematologic cancer	4.58e-06	6.48e-05	CcSEcCtD
Pazopanib—Nausea—Irinotecan—hematologic cancer	4.58e-06	6.48e-05	CcSEcCtD
Pazopanib—Infection—Prednisone—hematologic cancer	4.57e-06	6.46e-05	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—hematologic cancer	4.57e-06	6.45e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.56e-06	6.44e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.56e-06	6.44e-05	CcSEcCtD
Pazopanib—Fatigue—Betamethasone—hematologic cancer	4.56e-06	6.43e-05	CcSEcCtD
Pazopanib—Fatigue—Dexamethasone—hematologic cancer	4.56e-06	6.43e-05	CcSEcCtD
Pazopanib—Chills—Epirubicin—hematologic cancer	4.55e-06	6.42e-05	CcSEcCtD
Pazopanib—Pruritus—Etoposide—hematologic cancer	4.54e-06	6.42e-05	CcSEcCtD
Pazopanib—Shock—Prednisone—hematologic cancer	4.53e-06	6.39e-05	CcSEcCtD
Pazopanib—Pain—Betamethasone—hematologic cancer	4.52e-06	6.38e-05	CcSEcCtD
Pazopanib—Pain—Dexamethasone—hematologic cancer	4.52e-06	6.38e-05	CcSEcCtD
Pazopanib—Nervous system disorder—Prednisone—hematologic cancer	4.51e-06	6.37e-05	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—hematologic cancer	4.48e-06	6.32e-05	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—hematologic cancer	4.47e-06	6.31e-05	CcSEcCtD
Pazopanib—Nausea—Gemcitabine—hematologic cancer	4.47e-06	6.31e-05	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—hematologic cancer	4.46e-06	6.29e-05	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisone—hematologic cancer	4.45e-06	6.28e-05	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—hematologic cancer	4.44e-06	6.27e-05	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—hematologic cancer	4.44e-06	6.27e-05	CcSEcCtD
Pazopanib—Rash—Cisplatin—hematologic cancer	4.42e-06	6.24e-05	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—hematologic cancer	4.41e-06	6.24e-05	CcSEcCtD
Pazopanib—Erythema—Epirubicin—hematologic cancer	4.41e-06	6.23e-05	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—hematologic cancer	4.41e-06	6.23e-05	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—hematologic cancer	4.39e-06	6.2e-05	CcSEcCtD
Pazopanib—Anorexia—Prednisone—hematologic cancer	4.39e-06	6.2e-05	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—hematologic cancer	4.38e-06	6.19e-05	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—hematologic cancer	4.36e-06	6.15e-05	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—hematologic cancer	4.35e-06	6.14e-05	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—hematologic cancer	4.35e-06	6.14e-05	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—hematologic cancer	4.35e-06	6.14e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Betamethasone—hematologic cancer	4.32e-06	6.1e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.32e-06	6.1e-05	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—hematologic cancer	4.32e-06	6.1e-05	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—hematologic cancer	4.25e-06	6.01e-05	CcSEcCtD
Pazopanib—Dizziness—Etoposide—hematologic cancer	4.25e-06	6e-05	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—hematologic cancer	4.24e-06	5.99e-05	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—hematologic cancer	4.22e-06	5.97e-05	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—hematologic cancer	4.22e-06	5.96e-05	CcSEcCtD
Pazopanib—Chills—Doxorubicin—hematologic cancer	4.21e-06	5.94e-05	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.19e-06	5.92e-05	CcSEcCtD
Pazopanib—Dizziness—Prednisolone—hematologic cancer	4.19e-06	5.91e-05	CcSEcCtD
Pazopanib—Asthenia—Triamcinolone—hematologic cancer	4.18e-06	5.9e-05	CcSEcCtD
Pazopanib—Abdominal pain—Dexamethasone—hematologic cancer	4.18e-06	5.9e-05	CcSEcCtD
Pazopanib—Abdominal pain—Betamethasone—hematologic cancer	4.18e-06	5.9e-05	CcSEcCtD
Pazopanib—Nausea—Cisplatin—hematologic cancer	4.16e-06	5.88e-05	CcSEcCtD
Pazopanib—Insomnia—Prednisone—hematologic cancer	4.16e-06	5.88e-05	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—hematologic cancer	4.16e-06	5.87e-05	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—hematologic cancer	4.14e-06	5.85e-05	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—hematologic cancer	4.13e-06	5.84e-05	CcSEcCtD
Pazopanib—Pruritus—Triamcinolone—hematologic cancer	4.12e-06	5.82e-05	CcSEcCtD
Pazopanib—Cough—Methotrexate—hematologic cancer	4.11e-06	5.81e-05	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—hematologic cancer	4.11e-06	5.8e-05	CcSEcCtD
Pazopanib—Vomiting—Etoposide—hematologic cancer	4.08e-06	5.77e-05	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—hematologic cancer	4.08e-06	5.76e-05	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—hematologic cancer	4.08e-06	5.76e-05	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—hematologic cancer	4.08e-06	5.76e-05	CcSEcCtD
Pazopanib—Dyspepsia—Prednisone—hematologic cancer	4.05e-06	5.72e-05	CcSEcCtD
Pazopanib—Rash—Etoposide—hematologic cancer	4.05e-06	5.72e-05	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—hematologic cancer	4.04e-06	5.71e-05	CcSEcCtD
Pazopanib—Headache—Etoposide—hematologic cancer	4.02e-06	5.68e-05	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—hematologic cancer	4.02e-06	5.68e-05	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—hematologic cancer	4.01e-06	5.67e-05	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—hematologic cancer	4.01e-06	5.67e-05	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—hematologic cancer	4.01e-06	5.67e-05	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—hematologic cancer	4e-06	5.65e-05	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—hematologic cancer	4e-06	5.64e-05	CcSEcCtD
Pazopanib—Rash—Prednisolone—hematologic cancer	3.99e-06	5.64e-05	CcSEcCtD
Pazopanib—Dermatitis—Prednisolone—hematologic cancer	3.99e-06	5.63e-05	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.98e-06	5.63e-05	CcSEcCtD
Pazopanib—Fatigue—Prednisone—hematologic cancer	3.97e-06	5.6e-05	CcSEcCtD
Pazopanib—Headache—Prednisolone—hematologic cancer	3.97e-06	5.6e-05	CcSEcCtD
Pazopanib—Syncope—Epirubicin—hematologic cancer	3.95e-06	5.59e-05	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—hematologic cancer	3.95e-06	5.57e-05	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—hematologic cancer	3.92e-06	5.54e-05	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—hematologic cancer	3.88e-06	5.47e-05	CcSEcCtD
Pazopanib—Dizziness—Triamcinolone—hematologic cancer	3.85e-06	5.44e-05	CcSEcCtD
Pazopanib—Cough—Epirubicin—hematologic cancer	3.85e-06	5.43e-05	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—hematologic cancer	3.85e-06	5.43e-05	CcSEcCtD
Pazopanib—Infection—Methotrexate—hematologic cancer	3.82e-06	5.4e-05	CcSEcCtD
Pazopanib—Nausea—Etoposide—hematologic cancer	3.81e-06	5.39e-05	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—hematologic cancer	3.81e-06	5.38e-05	CcSEcCtD
Pazopanib—Asthenia—Dexamethasone—hematologic cancer	3.79e-06	5.35e-05	CcSEcCtD
Pazopanib—Asthenia—Betamethasone—hematologic cancer	3.79e-06	5.35e-05	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—hematologic cancer	3.77e-06	5.33e-05	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—hematologic cancer	3.77e-06	5.33e-05	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—hematologic cancer	3.77e-06	5.32e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—hematologic cancer	3.76e-06	5.31e-05	CcSEcCtD
Pazopanib—Nausea—Prednisolone—hematologic cancer	3.76e-06	5.31e-05	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—hematologic cancer	3.75e-06	5.3e-05	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—hematologic cancer	3.75e-06	5.3e-05	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—hematologic cancer	3.75e-06	5.3e-05	CcSEcCtD
Pazopanib—Pruritus—Betamethasone—hematologic cancer	3.74e-06	5.28e-05	CcSEcCtD
Pazopanib—Pruritus—Dexamethasone—hematologic cancer	3.74e-06	5.28e-05	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—hematologic cancer	3.74e-06	5.28e-05	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.73e-06	5.27e-05	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—hematologic cancer	3.72e-06	5.25e-05	CcSEcCtD
Pazopanib—Vomiting—Triamcinolone—hematologic cancer	3.7e-06	5.23e-05	CcSEcCtD
Pazopanib—Rash—Triamcinolone—hematologic cancer	3.67e-06	5.19e-05	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—hematologic cancer	3.67e-06	5.19e-05	CcSEcCtD
Pazopanib—Dermatitis—Triamcinolone—hematologic cancer	3.67e-06	5.18e-05	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—hematologic cancer	3.67e-06	5.18e-05	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—hematologic cancer	3.66e-06	5.17e-05	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—hematologic cancer	3.65e-06	5.16e-05	CcSEcCtD
Pazopanib—Headache—Triamcinolone—hematologic cancer	3.65e-06	5.15e-05	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—hematologic cancer	3.64e-06	5.14e-05	CcSEcCtD
Pazopanib—Diarrhoea—Dexamethasone—hematologic cancer	3.62e-06	5.11e-05	CcSEcCtD
Pazopanib—Diarrhoea—Betamethasone—hematologic cancer	3.62e-06	5.11e-05	CcSEcCtD
Pazopanib—Oedema—Epirubicin—hematologic cancer	3.6e-06	5.08e-05	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—hematologic cancer	3.59e-06	5.06e-05	CcSEcCtD
Pazopanib—Infection—Epirubicin—hematologic cancer	3.58e-06	5.05e-05	CcSEcCtD
Pazopanib—Cough—Doxorubicin—hematologic cancer	3.56e-06	5.03e-05	CcSEcCtD
Pazopanib—Shock—Epirubicin—hematologic cancer	3.54e-06	5e-05	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—hematologic cancer	3.53e-06	4.98e-05	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—hematologic cancer	3.52e-06	4.98e-05	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—hematologic cancer	3.52e-06	4.98e-05	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.5e-06	4.95e-05	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—hematologic cancer	3.5e-06	4.94e-05	CcSEcCtD
Pazopanib—Dizziness—Dexamethasone—hematologic cancer	3.49e-06	4.93e-05	CcSEcCtD
Pazopanib—Dizziness—Betamethasone—hematologic cancer	3.49e-06	4.93e-05	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—hematologic cancer	3.48e-06	4.91e-05	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—hematologic cancer	3.48e-06	4.91e-05	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—hematologic cancer	3.47e-06	4.91e-05	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—hematologic cancer	3.47e-06	4.91e-05	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—hematologic cancer	3.47e-06	4.91e-05	CcSEcCtD
Pazopanib—Nausea—Triamcinolone—hematologic cancer	3.46e-06	4.89e-05	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—hematologic cancer	3.45e-06	4.88e-05	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.45e-06	4.87e-05	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—hematologic cancer	3.43e-06	4.85e-05	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—hematologic cancer	3.43e-06	4.84e-05	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—hematologic cancer	3.42e-06	4.83e-05	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—hematologic cancer	3.4e-06	4.8e-05	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—hematologic cancer	3.39e-06	4.78e-05	CcSEcCtD
Pazopanib—Vomiting—Dexamethasone—hematologic cancer	3.36e-06	4.74e-05	CcSEcCtD
Pazopanib—Vomiting—Betamethasone—hematologic cancer	3.36e-06	4.74e-05	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—hematologic cancer	3.34e-06	4.72e-05	CcSEcCtD
Pazopanib—Rash—Betamethasone—hematologic cancer	3.33e-06	4.71e-05	CcSEcCtD
Pazopanib—Rash—Dexamethasone—hematologic cancer	3.33e-06	4.71e-05	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—hematologic cancer	3.33e-06	4.7e-05	CcSEcCtD
Pazopanib—Dermatitis—Dexamethasone—hematologic cancer	3.33e-06	4.7e-05	CcSEcCtD
Pazopanib—Dermatitis—Betamethasone—hematologic cancer	3.33e-06	4.7e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.32e-06	4.69e-05	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—hematologic cancer	3.32e-06	4.68e-05	CcSEcCtD
Pazopanib—Headache—Betamethasone—hematologic cancer	3.31e-06	4.68e-05	CcSEcCtD
Pazopanib—Headache—Dexamethasone—hematologic cancer	3.31e-06	4.68e-05	CcSEcCtD
Pazopanib—Infection—Doxorubicin—hematologic cancer	3.31e-06	4.67e-05	CcSEcCtD
Pazopanib—Asthenia—Prednisone—hematologic cancer	3.3e-06	4.66e-05	CcSEcCtD
Pazopanib—Pain—Methotrexate—hematologic cancer	3.29e-06	4.64e-05	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.28e-06	4.63e-05	CcSEcCtD
Pazopanib—Shock—Doxorubicin—hematologic cancer	3.28e-06	4.63e-05	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—hematologic cancer	3.27e-06	4.61e-05	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—hematologic cancer	3.26e-06	4.6e-05	CcSEcCtD
Pazopanib—Pruritus—Prednisone—hematologic cancer	3.26e-06	4.6e-05	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—hematologic cancer	3.26e-06	4.6e-05	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—hematologic cancer	3.23e-06	4.57e-05	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—hematologic cancer	3.23e-06	4.56e-05	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—hematologic cancer	3.22e-06	4.55e-05	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—hematologic cancer	3.21e-06	4.53e-05	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—hematologic cancer	3.2e-06	4.52e-05	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—hematologic cancer	3.17e-06	4.48e-05	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—hematologic cancer	3.17e-06	4.47e-05	CcSEcCtD
Pazopanib—Diarrhoea—Prednisone—hematologic cancer	3.15e-06	4.45e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—hematologic cancer	3.14e-06	4.44e-05	CcSEcCtD
Pazopanib—Nausea—Dexamethasone—hematologic cancer	3.14e-06	4.43e-05	CcSEcCtD
Pazopanib—Nausea—Betamethasone—hematologic cancer	3.14e-06	4.43e-05	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—hematologic cancer	3.13e-06	4.42e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.11e-06	4.39e-05	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—hematologic cancer	3.1e-06	4.38e-05	CcSEcCtD
Pazopanib—Pain—Epirubicin—hematologic cancer	3.08e-06	4.35e-05	CcSEcCtD
Pazopanib—Dizziness—Prednisone—hematologic cancer	3.04e-06	4.3e-05	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—hematologic cancer	3.04e-06	4.29e-05	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.03e-06	4.28e-05	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—hematologic cancer	3.01e-06	4.25e-05	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—hematologic cancer	2.99e-06	4.22e-05	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—hematologic cancer	2.97e-06	4.19e-05	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—hematologic cancer	2.96e-06	4.18e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—hematologic cancer	2.94e-06	4.16e-05	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—hematologic cancer	2.93e-06	4.14e-05	CcSEcCtD
Pazopanib—Vomiting—Prednisone—hematologic cancer	2.93e-06	4.13e-05	CcSEcCtD
Pazopanib—Rash—Prednisone—hematologic cancer	2.9e-06	4.1e-05	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—hematologic cancer	2.9e-06	4.09e-05	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—hematologic cancer	2.89e-06	4.09e-05	CcSEcCtD
Pazopanib—Headache—Prednisone—hematologic cancer	2.88e-06	4.07e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.87e-06	4.06e-05	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—hematologic cancer	2.87e-06	4.05e-05	CcSEcCtD
Pazopanib—Pain—Doxorubicin—hematologic cancer	2.85e-06	4.02e-05	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—hematologic cancer	2.84e-06	4.02e-05	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—hematologic cancer	2.76e-06	3.9e-05	CcSEcCtD
Pazopanib—Nausea—Prednisone—hematologic cancer	2.73e-06	3.86e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.72e-06	3.85e-05	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—hematologic cancer	2.72e-06	3.84e-05	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—hematologic cancer	2.63e-06	3.72e-05	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—hematologic cancer	2.63e-06	3.72e-05	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—hematologic cancer	2.58e-06	3.65e-05	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—hematologic cancer	2.55e-06	3.6e-05	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—hematologic cancer	2.54e-06	3.59e-05	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—hematologic cancer	2.46e-06	3.48e-05	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—hematologic cancer	2.45e-06	3.45e-05	CcSEcCtD
Pazopanib—Rash—Methotrexate—hematologic cancer	2.42e-06	3.42e-05	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—hematologic cancer	2.42e-06	3.42e-05	CcSEcCtD
Pazopanib—Headache—Methotrexate—hematologic cancer	2.41e-06	3.4e-05	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—hematologic cancer	2.39e-06	3.37e-05	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—hematologic cancer	2.38e-06	3.36e-05	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—hematologic cancer	2.36e-06	3.33e-05	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—hematologic cancer	2.29e-06	3.23e-05	CcSEcCtD
Pazopanib—Nausea—Methotrexate—hematologic cancer	2.28e-06	3.23e-05	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—hematologic cancer	2.28e-06	3.22e-05	CcSEcCtD
Pazopanib—Rash—Epirubicin—hematologic cancer	2.27e-06	3.2e-05	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—hematologic cancer	2.27e-06	3.2e-05	CcSEcCtD
Pazopanib—Headache—Epirubicin—hematologic cancer	2.25e-06	3.18e-05	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—hematologic cancer	2.2e-06	3.11e-05	CcSEcCtD
Pazopanib—Nausea—Epirubicin—hematologic cancer	2.14e-06	3.02e-05	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—hematologic cancer	2.12e-06	2.99e-05	CcSEcCtD
Pazopanib—Rash—Doxorubicin—hematologic cancer	2.1e-06	2.97e-05	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—hematologic cancer	2.1e-06	2.96e-05	CcSEcCtD
Pazopanib—Headache—Doxorubicin—hematologic cancer	2.09e-06	2.95e-05	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—hematologic cancer	1.98e-06	2.79e-05	CcSEcCtD
Pazopanib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.5e-07	2.32e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—hematologic cancer	1.5e-07	2.32e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.5e-07	2.32e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—hematologic cancer	1.5e-07	2.31e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—hematologic cancer	1.5e-07	2.31e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—JUN—hematologic cancer	1.5e-07	2.31e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—hematologic cancer	1.49e-07	2.3e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SRC—hematologic cancer	1.49e-07	2.3e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SRC—hematologic cancer	1.49e-07	2.3e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—hematologic cancer	1.48e-07	2.29e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NCOR1—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK3—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FGF2—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.48e-07	2.28e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—hematologic cancer	1.47e-07	2.27e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—hematologic cancer	1.47e-07	2.26e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—hematologic cancer	1.47e-07	2.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—hematologic cancer	1.46e-07	2.26e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—hematologic cancer	1.46e-07	2.25e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYCS—hematologic cancer	1.46e-07	2.25e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—hematologic cancer	1.46e-07	2.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3R1—hematologic cancer	1.46e-07	2.25e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.45e-07	2.24e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—hematologic cancer	1.45e-07	2.23e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—hematologic cancer	1.45e-07	2.23e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—hematologic cancer	1.44e-07	2.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—hematologic cancer	1.44e-07	2.21e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—hematologic cancer	1.43e-07	2.21e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—hematologic cancer	1.43e-07	2.2e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—hematologic cancer	1.42e-07	2.2e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—hematologic cancer	1.42e-07	2.19e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—hematologic cancer	1.42e-07	2.19e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—hematologic cancer	1.42e-07	2.19e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—hematologic cancer	1.42e-07	2.19e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK8—hematologic cancer	1.42e-07	2.18e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JAK2—hematologic cancer	1.41e-07	2.18e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—hematologic cancer	1.41e-07	2.18e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—hematologic cancer	1.41e-07	2.17e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—hematologic cancer	1.4e-07	2.16e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.4e-07	2.16e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—hematologic cancer	1.4e-07	2.16e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—hematologic cancer	1.4e-07	2.15e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.39e-07	2.15e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.39e-07	2.15e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK8—hematologic cancer	1.39e-07	2.14e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—hematologic cancer	1.39e-07	2.14e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—hematologic cancer	1.38e-07	2.13e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—hematologic cancer	1.38e-07	2.13e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—hematologic cancer	1.38e-07	2.13e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—hematologic cancer	1.38e-07	2.13e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—hematologic cancer	1.38e-07	2.12e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—hematologic cancer	1.37e-07	2.12e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—hematologic cancer	1.37e-07	2.12e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—hematologic cancer	1.37e-07	2.11e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—hematologic cancer	1.37e-07	2.11e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—hematologic cancer	1.36e-07	2.1e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—hematologic cancer	1.35e-07	2.08e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—hematologic cancer	1.35e-07	2.08e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—hematologic cancer	1.35e-07	2.08e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	1.34e-07	2.07e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—hematologic cancer	1.34e-07	2.07e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	1.34e-07	2.07e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—hematologic cancer	1.34e-07	2.06e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—hematologic cancer	1.33e-07	2.06e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—hematologic cancer	1.33e-07	2.06e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—hematologic cancer	1.33e-07	2.05e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—hematologic cancer	1.33e-07	2.05e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—hematologic cancer	1.33e-07	2.04e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.32e-07	2.04e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—hematologic cancer	1.32e-07	2.04e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—hematologic cancer	1.31e-07	2.03e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.31e-07	2.02e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	1.31e-07	2.02e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—hematologic cancer	1.3e-07	2.01e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.3e-07	2.01e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—hematologic cancer	1.3e-07	2.01e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	1.29e-07	2e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	1.29e-07	2e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	1.29e-07	1.99e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—hematologic cancer	1.29e-07	1.99e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—hematologic cancer	1.29e-07	1.99e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.29e-07	1.98e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—hematologic cancer	1.28e-07	1.98e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—hematologic cancer	1.28e-07	1.97e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—hematologic cancer	1.27e-07	1.96e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—hematologic cancer	1.27e-07	1.96e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—hematologic cancer	1.27e-07	1.96e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—hematologic cancer	1.26e-07	1.95e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—hematologic cancer	1.26e-07	1.95e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—hematologic cancer	1.26e-07	1.95e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	1.26e-07	1.95e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.26e-07	1.95e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.24e-07	1.92e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—hematologic cancer	1.24e-07	1.91e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	1.24e-07	1.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—hematologic cancer	1.24e-07	1.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—hematologic cancer	1.23e-07	1.9e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—hematologic cancer	1.23e-07	1.9e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.23e-07	1.9e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—hematologic cancer	1.22e-07	1.88e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.22e-07	1.88e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—hematologic cancer	1.21e-07	1.87e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—hematologic cancer	1.2e-07	1.86e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—hematologic cancer	1.2e-07	1.86e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	1.2e-07	1.86e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—hematologic cancer	1.2e-07	1.85e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	1.2e-07	1.85e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—hematologic cancer	1.2e-07	1.85e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—hematologic cancer	1.19e-07	1.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CD44—hematologic cancer	1.19e-07	1.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.19e-07	1.84e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.18e-07	1.82e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.18e-07	1.82e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—hematologic cancer	1.18e-07	1.82e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—hematologic cancer	1.18e-07	1.82e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—hematologic cancer	1.17e-07	1.81e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—hematologic cancer	1.17e-07	1.81e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—hematologic cancer	1.17e-07	1.81e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.17e-07	1.8e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	1.16e-07	1.8e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—hematologic cancer	1.16e-07	1.79e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—hematologic cancer	1.16e-07	1.79e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—hematologic cancer	1.14e-07	1.75e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK8—hematologic cancer	1.14e-07	1.75e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—hematologic cancer	1.13e-07	1.75e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—hematologic cancer	1.13e-07	1.74e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.13e-07	1.74e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—hematologic cancer	1.12e-07	1.73e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—hematologic cancer	1.12e-07	1.73e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.12e-07	1.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	1.11e-07	1.71e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.11e-07	1.71e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—hematologic cancer	1.11e-07	1.71e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—hematologic cancer	1.11e-07	1.71e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—hematologic cancer	1.1e-07	1.7e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.1e-07	1.7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—hematologic cancer	1.1e-07	1.69e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—hematologic cancer	1.09e-07	1.69e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—hematologic cancer	1.09e-07	1.68e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—hematologic cancer	1.08e-07	1.67e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—hematologic cancer	1.08e-07	1.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—hematologic cancer	1.08e-07	1.66e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—hematologic cancer	1.06e-07	1.64e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—hematologic cancer	1.05e-07	1.62e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—hematologic cancer	1.05e-07	1.62e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—hematologic cancer	1.05e-07	1.62e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.05e-07	1.62e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.04e-07	1.61e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—hematologic cancer	1.04e-07	1.6e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—hematologic cancer	1.04e-07	1.6e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—hematologic cancer	1.04e-07	1.6e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.04e-07	1.6e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—hematologic cancer	1.04e-07	1.6e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	1.02e-07	1.58e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	1.02e-07	1.58e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—hematologic cancer	1.02e-07	1.57e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—hematologic cancer	1.01e-07	1.55e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—hematologic cancer	1e-07	1.55e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	9.99e-08	1.54e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—hematologic cancer	9.96e-08	1.54e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—hematologic cancer	9.92e-08	1.53e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.92e-08	1.53e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	9.87e-08	1.52e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—hematologic cancer	9.78e-08	1.51e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—hematologic cancer	9.67e-08	1.49e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	9.66e-08	1.49e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—hematologic cancer	9.66e-08	1.49e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—hematologic cancer	9.65e-08	1.49e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—hematologic cancer	9.63e-08	1.49e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.6e-08	1.48e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—hematologic cancer	9.56e-08	1.47e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—hematologic cancer	9.53e-08	1.47e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—hematologic cancer	9.49e-08	1.46e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	9.44e-08	1.46e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.39e-08	1.45e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—hematologic cancer	9.28e-08	1.43e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—hematologic cancer	9.26e-08	1.43e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—hematologic cancer	9.25e-08	1.43e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.2e-08	1.42e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—hematologic cancer	9.14e-08	1.41e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3R1—hematologic cancer	9.12e-08	1.41e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NCOR1—hematologic cancer	9.11e-08	1.41e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—hematologic cancer	9.11e-08	1.41e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	9.1e-08	1.4e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	9.04e-08	1.39e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—hematologic cancer	8.98e-08	1.39e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—hematologic cancer	8.92e-08	1.38e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—hematologic cancer	8.85e-08	1.37e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.77e-08	1.35e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.59e-08	1.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—hematologic cancer	8.42e-08	1.3e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—hematologic cancer	8.37e-08	1.29e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—hematologic cancer	8.35e-08	1.29e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	8.34e-08	1.29e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	8.19e-08	1.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—hematologic cancer	8.16e-08	1.26e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—hematologic cancer	8.13e-08	1.25e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.05e-08	1.24e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—hematologic cancer	7.96e-08	1.23e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.93e-08	1.22e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—hematologic cancer	7.92e-08	1.22e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—hematologic cancer	7.75e-08	1.2e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.71e-08	1.19e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—hematologic cancer	7.61e-08	1.17e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—hematologic cancer	7.58e-08	1.17e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	7.28e-08	1.12e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—hematologic cancer	7.27e-08	1.12e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—hematologic cancer	7.25e-08	1.12e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—hematologic cancer	6.94e-08	1.07e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—hematologic cancer	6.85e-08	1.06e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.77e-08	1.04e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.72e-08	1.04e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—hematologic cancer	6.69e-08	1.03e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—hematologic cancer	6.54e-08	1.01e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.27e-08	9.68e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.95e-08	9.18e-07	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	5.89e-08	9.09e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—hematologic cancer	5.87e-08	9.06e-07	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—hematologic cancer	5.81e-08	8.96e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.62e-08	8.67e-07	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—hematologic cancer	5.54e-08	8.54e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.19e-08	8e-07	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—hematologic cancer	5.13e-08	7.92e-07	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.84e-08	7.46e-07	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—hematologic cancer	4.81e-08	7.42e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—hematologic cancer	4.48e-08	6.92e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—hematologic cancer	4.27e-08	6.59e-07	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—hematologic cancer	4.19e-08	6.47e-07	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	4.1e-08	6.32e-07	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—hematologic cancer	3.95e-08	6.1e-07	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—hematologic cancer	3.35e-08	5.16e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.16e-08	4.88e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.58e-08	3.99e-07	CbGpPWpGaD
